Xencor, Inc. - Product Pipeline Review

Global Markets Direct’s, ‘Xencor, Inc. - Product Pipeline Review - 2016’, provides an overview of the Xencor, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Xencor, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Xencor, Inc.

The report provides overview of Xencor, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Xencor, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Xencor, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Xencor, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Xencor, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Xencor, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Xencor, Inc. Snapshot 6

Xencor, Inc. Overview 6

Key Information ...

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Xencor, Inc. Snapshot 6

Xencor, Inc. Overview 6

Key Information 6

Key Facts 6

Xencor, Inc. - Research and Development Overview 7

Key Therapeutic Areas 7

Xencor, Inc. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Pipeline Products - Out-Licensed Products 14

Out-Licensed Products/Combination Treatment Modalities 15

Xencor, Inc. - Pipeline Products Glance 16

Xencor, Inc. - Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Xencor, Inc. - Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

Discovery Products/Combination Treatment Modalities 19

Xencor, Inc. - Drug Profiles 20

XmAb-5871 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

Monoclonal Antibody 1 for Oncology 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Monoclonal Antibody 2 for Oncology 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

XmAb-7195 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

XENP-1138 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

XmAb-13676 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

XmAb-13677 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

XmAb-14045 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

XmAb-14484 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

XmAb-18087 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

XmAb-19722 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

XmAb-20717 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

XmAb-6755 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Monoclonal Antibody to Agonize CD32b for Immunology 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Monoclonal Antibody to Agonize CD32b for Undisclosed Indication 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Xencor, Inc. - Pipeline Analysis 36

Xencor, Inc. - Pipeline Products by Target 36

Xencor, Inc. - Pipeline Products by Route of Administration 38

Xencor, Inc. - Pipeline Products by Molecule Type 39

Xencor, Inc. - Pipeline Products by Mechanism of Action 40

Xencor, Inc. - Recent Pipeline Updates 41

Xencor, Inc. - Dormant Projects 45

Xencor, Inc. - Locations And Subsidiaries 46

Head Office 46

Other Locations & Subsidiaries 46

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

List of Tables

Xencor, Inc., Key Information 6

Xencor, Inc., Key Facts 6

Xencor, Inc. - Pipeline by Indication, 2016 8

Xencor, Inc. - Pipeline ...

List of Tables

Xencor, Inc., Key Information 6

Xencor, Inc., Key Facts 6

Xencor, Inc. - Pipeline by Indication, 2016 8

Xencor, Inc. - Pipeline by Stage of Development, 2016 10

Xencor, Inc. - Monotherapy Products in Pipeline, 2016 11

Xencor, Inc. - Partnered Products in Pipeline, 2016 12

Xencor, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 13

Xencor, Inc. - Out-Licensed Products in Pipeline, 2016 14

Xencor, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 15

Xencor, Inc. - Phase II, 2016 16

Xencor, Inc. - Phase I, 2016 17

Xencor, Inc. - Preclinical, 2016 18

Xencor, Inc. - Discovery, 2016 19

Xencor, Inc. - Pipeline by Target, 2016 37

Xencor, Inc. - Pipeline by Route of Administration, 2016 38

Xencor, Inc. - Pipeline by Molecule Type, 2016 39

Xencor, Inc. - Pipeline Products by Mechanism of Action, 2016 40

Xencor, Inc. - Recent Pipeline Updates, 2016 41

Xencor, Inc. - Dormant Developmental Projects,2016 45

Xencor, Inc., Other Locations 46

List of Figures

List of Figures

Xencor, Inc. - Pipeline by Indication, 2016 8

Xencor, Inc. - Pipeline by Stage of Development, 2016 10

Xencor, Inc. - Monotherapy ...

List of Figures

Xencor, Inc. - Pipeline by Indication, 2016 8

Xencor, Inc. - Pipeline by Stage of Development, 2016 10

Xencor, Inc. - Monotherapy Products in Pipeline, 2016 11

Xencor, Inc. - Partnered Products in Pipeline, 2016 12

Xencor, Inc. - Out-Licensed Products in Pipeline, 2016 14

Xencor, Inc. - Pipeline by Top 10 Target, 2016 36

Xencor, Inc. - Pipeline by Route of Administration, 2016 38

Xencor, Inc. - Pipeline by Molecule Type, 2016 39

Xencor, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 40

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports